{"id":"W3004787369","doi":"10.1200/jco.2020.38.4_suppl.491","title":"Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Cabozantinib; Hepatocellular carcinoma; Internal medicine; Regimen; Regorafenib; Ramucirumab; Population; Oncology; Cancer; Surgery; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001014624,0.000204624,0.001676289,0.00008815809,0.00003389992,0.000005052646,0.0001621592,0.0001836417,0.0001874097],"category_scores_gemma":[0.0009773955,0.0001389188,0.0002879896,0.0002324032,0.00007435956,0.0001402886,0.00001746243,0.0006751587,0.000001238347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000326976,"about_ca_system_score_gemma":0.001476451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005901959,"about_ca_topic_score_gemma":0.0002094426,"domain_scores_codex":[0.9966857,0.0002754786,0.002047774,0.0003421011,0.0003902254,0.0002586982],"domain_scores_gemma":[0.9961137,0.001038245,0.00149747,0.0002178702,0.0007870345,0.0003457113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06059146,0.002633398,0.8403245,0.00004056942,0.000169525,0.00005041836,0.0001651248,0.0004939014,0.00004393527,0.000002042095,0.00001895145,0.09546617],"study_design_scores_gemma":[0.05641706,0.04628206,0.8922672,0.00005600234,0.0001007731,0.000001861156,0.00009938511,0.0005942777,0.0001046712,0.00008125103,0.003868498,0.000126939],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920684,0.0004266315,0.0006563986,0.004902806,0.0003529242,0.001546478,0.000020585,0.00001321032,0.00001255543],"genre_scores_gemma":[0.9899786,0.0000181766,0.004056734,0.005238136,0.0005899806,0.00005984533,0.00001165486,0.00003552801,0.00001132245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09533923,"threshold_uncertainty_score":0.5664943,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1042699116533265,"score_gpt":0.4551533919903907,"score_spread":0.3508834803370642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}